CDC/Janice Haney CarrShopping spree at Eli Lilly? The US pharma giant is acquiring no fewer than three companies, all active in infectious diseases. Among them is Swiss biotech LimmaTech Biologics AG, led by former CureVac CEO Franz-Werner Haas. Yet Lilly’s ambitions extend well beyond classical infectious disease markets, targeting areas ranging from autoimmune disorders and antimicrobial resistance to chronic immune dysfunction and even cancer.
Tag Archive for: AMR
David Dorward; Ph.D.; National Institute of Allergy and Infectious Diseases (NIAID)Amid chronic under-investments in new antibacterial weapons, Basilea Pharmaceutica has secured an additional US$6 million from CARB‑X to fund the first‑in‑human Phase I trial of a novel Gram‑negative antibiotic now entering early clinical development. The compound BAL2420 targets LptA, part of the lipopolysaccharide transport bridge that Gram negative bacteria rely on to build their outer membrane.
CARB-XCombating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is an industry alliance to support research and development projects in AMR. Since its inception in 2016, CARB-X has supported 114 R&D projects across 14 countries, leading to 18 projects advancing into or completing clinical trials. EBM talked to CARB-X Executive Director Kevin Outterson.
Image by freepikAntimicrobial resistance (AMR) poses a huge threat to the prevention and treatment of a growing number of infections caused by bacteria, parasites, viruses, and fungi. A public-private partnership involving nine European projects and 98 organisations is now calling for long-term investment to maintain Europe’s ability to research and develop new antibiotics.
Amiferia ABSwedish antimicrobial specialist Amferia AB has inked a contract is with the Swiss animal health company Biokema SA for commercialisation of Amferia’s proprietary antimicrobial wound care technology in Switzerland.
A Dutch-German resarch team together with Evotec SE have presented a new class of vancomycin derivatives with good safety profile that kill multi-resistant, Gram-positive bugs.
Swiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Novo Nordisk Foundation has partnered with CARB-X investing US$25m to help SMEs to fight drug-resistant infections.
Hoffmann-La Roche AG has published details on the mechanism of action of its Phase I antibiotic Zosurabalpin (RG6006) that kills the carbapenem-resistant bug Acinetobacter baumannii.
.
Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors.